[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367792-105":59,"doc-detail-367792-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","patient-and-physician-preferences-for-cancer-panel-testing-in-japan-a-best-worst-scaling-study","Patient and physician preferences for cancer panel testing in Japan - a best-worst scaling study","","Examines how patients and physicians in Japan value the benefits and burdens of comprehensive genomic profiling (CGP) panel testing. Uses a cross-sectional, mixed-method preference elicitation design centered on best-worst scaling (BWS), including qualitative work to define attributes and pilot the survey. Surveys 229 patients with lung or rare cancers and 329 treating physicians. Reports patient priorities emphasizing that all samples yield results, direct out-of-pocket cost of ¥0, and blood sampling; physicians emphasize key attribute levels and identify cost, testing duration, and the risk of no-result outcomes as main negatives.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/patient-and-physician-preferences-for-cancer-panel-testing-in-japan-a-best-worst-scaling-study/367792/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/patient-and-physician-preferences-for-cancer-panel-testing-in-japan-a-best-worst-scaling-study/367792.png","ImageObject",300,407,{"name":92,"@type":93},"Aran","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the study?","Question",{"text":112,"@type":113},"To assess the relative importance of benefits and burdens of comprehensive genomic profiling testing from the perspectives of patients and physicians in Japan.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were preferences measured?",{"text":117,"@type":113},"The study used a cross-sectional preference elicitation approach centered on best-worst scaling (BWS), supported by qualitative stages to define attributes and pilot the survey.",{"name":119,"@type":110,"acceptedAnswer":120},"What benefits did patients consider most important for panel testing?",{"text":121,"@type":113},"Patients’ top benefit was that all samples would yield results, alongside valuing that the test cost paid by the patient is ¥0 and that the test uses a blood sample.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367792,1791028727,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Open access Original research  \nTo cite: Suehara Y, Hasegawa K, Majima Y, et al. Patient and physician preferences for cancer panel testing in Japan: a best-worst scaling  \nstudy. BMJ Open 2025;15:e097620 . doi:10 . 1136/ bmjopen-2024-097620  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2024-097620](bmjopen-2024-097620)) .  \nReceived 06 December 2024 Accepted 07 August 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan  \n2Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan 3NPO Lung Cancer Patients Association One Step, Kanagawa, Japan  \n4Rare Cancers Japan, Tokyo, Japan  \n5Bayer Yakuhin, Ltd, Tokyo, Japan  \n6Putnam, Lyon, France 7Putnam, Sofia, Bulgaria 8Department of Clinical Oncology, Juntendo University Graduate School of Medicine, Tokyo, Japan  \nCorrespondence to  \nNaoyuki Mita;  \n[naoyuki.mita@icloud.com](naoyuki.mita@icloud.com)  \nPatient and physician preferences for cancer panel testing in Japan: a best-worst scaling study  \nYoshiyuki Suehara,1,2 Kazuo Hasegawa,3 Yoshiyuki Majima,4 Naoyuki Mita  ,5 Sylvaine Barbier,6 Nataliya Bogoeva,7 Shunsuke Kato8  \nABSTRACT  \nObjective To examine the relative importance of the benefits and burdens of comprehensive genomic profiling testing from the perspectives of patients and physiciansin Japan.  \nDesign Cross-sectional preference elicitation via a mixed method centred on best-worst scaling (BWS) case 2 (profile case), including qualitative stages to define the attributes and pilot the survey.  \nSetting Online surveys for patients who are members of patient advocacy groups and for physicians registered with a survey panel.  \nParticipants A preference study was conducted among 229 patients with lung or rare cancers and 329 physicians treating lung or rare cancers.  \nPrimary and secondary outcome measures BWS scores indicating patient and physician preferences for comprehensive genomic profiling tests.  \nResults The best benefit of panel testing for the patients was that all samples would yield results (coefficient 5 .36) . They also valued that the cost of the test paid directly by the patient is ¥0 (coefficient 5 .28) and that a blood sample is used (coefficient 4 .87) . They perceived the cost of ¥800 000, duration of the testing process (3 months) and the lack of a detailed explanation of the test as the primary disadvantages (coefficients −0 .45, reference level, 0 .09, respectively) . The physicians highlighted the following essential attributes for panel testing: all samples will yield results, a blood sample is used and a sample collected in the past is used (coefficients 4 .66, 4 . 17, 4 . 10, respectively) . In their view, the most negative attribute level was that the cost of the test is ¥800 000, followed by the duration of the testing process (3 months) and the possibility that 4 in 10 tests will not yield results due to a problem with the sample (coefficients −0 .32, reference level, 0 .41, respectively) .  \nConclusions The results of this study provide insights that will help patients and physicians improve the panel testing process. The results will also guide the further development of panel testing technologies and the optimisation of regulatory and healthcare policies.  \nTrial registration number NCT04607889.  \nINTRODUCTION  \nPrecision medicine integrates molecular data and conventional clinical information to achieve optimal efficacy and avoid toxicity.  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ Patient and physician views on comprehensive genomic profiling testing were examined using a conjoint method for","cbCaivgaTboiJE5N","https://ap.wps.com/l/cbCaivgaTboiJE5N","pdf",1893643,11,"English","# Abstract\n# Introduction\n# Strengths and limitations of this study","[{\"question\":\"What was the main objective of the study?\",\"answer\":\"To assess the relative importance of benefits and burdens of comprehensive genomic profiling testing from the perspectives of patients and physicians in Japan.\"},{\"question\":\"How were preferences measured?\",\"answer\":\"The study used a cross-sectional preference elicitation approach centered on best-worst scaling (BWS), supported by qualitative stages to define attributes and pilot the survey.\"},{\"question\":\"What benefits did patients consider most important for panel testing?\",\"answer\":\"Patients’ top benefit was that all samples would yield results, alongside valuing that the test cost paid by the patient is ¥0 and that the test uses a blood sample.\"}]","Patient and physician preferences for cancer panel testing in Japan - a best-worst scaling study | PDF",1790172679,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a88e634168962f4b5480f9870fcc96c6.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e3fe3ed8a2f57546eee00b6e93bc87d.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65a02a9c747fd2c7ca85f5689cd83e08.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11bb7fda5ad186194e72595f8fa36d62.webp",980,1306]